India-based vaccine maker Bharat Biotech and Spanish biopharma player Biofabri commence the clinical trials of the world's first live attenuated vaccine of Mycobacterium tuberculosis isolated from a human, MTBVAC, to evaluate its safety, immunogenicity and efficacy.
Bharat Biotech International Ltd has initiated clinical trials for the Tuberculosis vaccine Mtbvac on adults in India. Developed by the Spanish biopharmaceutical company Biofabri, Mtbvac is the first TB vaccine derived from a human source. The vaccine aims to be more effective and longer-lasting than the current BCG vaccine for newborns and to prevent TB in adults and adolescents, for whom there is currently no effective vaccine. The trials are a significant step, especially in a country like India where 28% of the world s TB cases occur.
India Business News: HYDERABAD: The world’s first live attenuated vaccine of Mycobacterium tuberculosis isolated from a human, MTBVAC, developed by Spanish biopharma playe.
India News: HYDERABAD: Bharat Biotech, based in Hyderabad, has started clinical trials of MTBVAC, the world's first Mycobacterium tuberculosis vaccine derived fro.
A senior officer from health department requesting anonymity, said, that despite the widespread use of the BCG vaccine, there is still considerable debate on its effectiveness in preventing TB and the duration of immunity post-vaccination